miR‑152 may function as an early diagnostic and prognostic biomarker in patients with cervical intraepithelial neoplasia and patients with cervical cancer

Yang,Dongmei; Zhang,Qiumei

doi:10.3892/ol.2019.10233

miR‑152 may function as an early diagnostic and prognostic biomarker in patients with cervical intraepithelial neoplasia and patients with cervical cancer

Authors:
- Dongmei Yang
- Qiumei Zhang
View Affiliations

Affiliations: Department Two of Gynecology, Linyi People's Hospital, Linyi, Shandong 276003, P.R. China, Outpatient Department of Obstetrics and Gynecology, Linyi People's Hospital, Linyi, Shandong 276003, P.R. China
Published online on: April 9, 2019 https://doi.org/10.3892/ol.2019.10233
Pages: 5693-5698

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated that circulating miRNAs are effective biomarkers of various types of cancer. It has also been indicated that miR‑152 is upregulated in cervical cancer. However, whether miR‑152 may be used as an early detection method for patients with cervical cancer is yet to be elucidated. The results of the current study demonstrated that miR‑152 levels were the lowest in healthy controls, high in patients with cervical intraepithelial neoplasia (CIN), and the highest in patients with cervical cancer. Furthermore, miR‑152 levels in peripheral blood were higher in patients with high‑grade CIN compared with those with low‑grade CIN. It was also demonstrated that miR‑152 levels increased as the clinical stage of cervical cancer advanced. Compared with healthy controls, squamous cell carcinoma antigen (SSC‑Ag) levels were significantly higher in patients with cervical cancer. However, no significant differences were identified in patients with CIN, indicating that SCC‑Ag could not be used for the early detection of CIN. In contrast, miR‑152 was elevated along with SCC‑Ag in patients with CIN and cervical cancer. Receiver operating characteristic (ROC) analysis demonstrated that miR‑152 preferentially distinguished patients with CIN (95% confidence interval, 0.688‑0.973; P<0.001) and patients with cervical cancer (95% confidence interval, 0.817‑0.996; P<0.001) from healthy controls. Additionally, miR‑152 levels were markedly reduced in patients with cervical cancer who received chemotherapy (28 patients) or chemotherapy and radiation therapy (22 patients). In conclusion, the level of miR‑153 in peripheral blood may be utilized as an effective biomarker for the early detection of cervical cancer, thus decreasing the requirement for invasive cervical biopsies. Furthermore, it may be utilized to predict the most effective form of treatment for patients with cervical cancer.

View Figures

View References

1	Luttmer R, De Strooper LM, Steenbergen RD, Berkhof J, Snijders PJ, Heideman DA and Meijer CJ: Management of high-risk HPV-positive women for detection of cervical (pre)cancer. Expert Rev Mol Diagn. 16:961–974. 2016. View Article : Google Scholar : PubMed/NCBI
2	El-Zein M, Richardson L and Franco EL: Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. J Clin Virol. 76 (Suppl 1):S62–S68. 2016. View Article : Google Scholar : PubMed/NCBI
3	Jayasinghe Y, Rangiah C, Gorelik A, Ogilvie G, Wark JD, Hartley S and Garland SM: Primary HPV DNA based cervical cancer screening at 25 years: Views of young Australian women aged 16–28 years. J Clin Virol. 76 (Suppl 1):S74–S80. 2016. View Article : Google Scholar : PubMed/NCBI
4	Hasahya OT, Berggren V, Sematimba D, Nabirye RC and Kumakech E: Beliefs, perceptions and health-seeking behaviours in relation to cervical cancer: A qualitative study among women in Uganda following completion of an HPV vaccination campaign. Glob Health Action. 9:293362016. View Article : Google Scholar : PubMed/NCBI
5	Lofters A and Vahabi M: Self-sampling for HPV to enhance uptake of cervical cancer screening: Has the time come in Canada? CMAJ. 188:853–854. 2016. View Article : Google Scholar : PubMed/NCBI
6	Lowy DR: HPV vaccination to prevent cervical cancer and other HPV-associated disease: From basic science to effective interventions. J Clin Invest. 126:5–11. 2016. View Article : Google Scholar : PubMed/NCBI
7	Salvatici M, Achilarre MT, Sandri MT, Boveri S, Vanna Z and Landoni F: Squamous cell carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: Role in the early diagnosis of recurrence. Gynecol Oncol. 142:115–119. 2016. View Article : Google Scholar : PubMed/NCBI
8	Micke O, Prott FJ, Schäfer U, Tangerding S, Pötter R and Willich N: The impact of squamous cell carcinoma (SCC) antigen in the follow-up after radiotherapy in patients with cervical cancer. Anticancer Res. 20:5113–5115. 2000.PubMed/NCBI
9	Nozawa S, Kojima M, Tukazaki K, Sakayori M, Iizuka R and Kagiyama N: In vitro and in vivo induction of squamous cell carcinoma antigen (SCC) in a uterine cervical cancer cell line (SKG-IIIa) with peplomycin and sodium butyrate. Asia Oceania J Obstet Gynaecol. 16:153–160. 1990. View Article : Google Scholar : PubMed/NCBI
10	Yamashita Y, Uehara T, Hasegawa M, Deng Z, Matayoshi S, Kiyuna A, Kondo S, Maeda H, Ganaha A and Suzuki M: Squamous cell carcinoma antigen as a diagnostic marker of nasal inverted papilloma. Am J Rhinol Allergy. 30:122–127. 2016. View Article : Google Scholar : PubMed/NCBI
11	Yao J, Zhang P, Li J and Xu W: MicroRNA-215 acts as a tumor suppressor in breast cancer by targeting AKT serine/threonine kinase 1. Oncol Lett. 14:1097–1104. 2017. View Article : Google Scholar : PubMed/NCBI
12	Sempere LF, Keto J and Fabbri M: Exosomal MicroRNAs in breast cancer towards diagnostic and therapeutic applications. Cancers (Basel). 9:E712017. View Article : Google Scholar : PubMed/NCBI
13	Wang J, Yan F, Zhao Q, Zhan F, Wang R, Wang L, Zhang Y and Huang X: Circulating exosomal miR-125a-3p as a novel biomarker for early-stage colon cancer. Sci Rep. 7:41502017. View Article : Google Scholar : PubMed/NCBI
14	Zhang ZQ, Meng H, Wang N, Liang LN, Liu LN, Lu SM and Luan Y: Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol. 9:1352014. View Article : Google Scholar : PubMed/NCBI
15	Lacedonia D, Palladino GP, Foschino-Barbaro MP, Scioscia G and Carpagnano GE: Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma-COPD overlap syndrome phenotype. Int J Chron Obstruct Pulmon Dis. 12:1811–1817. 2017. View Article : Google Scholar : PubMed/NCBI
16	Zhang X, Yang R, Hu BL, Lu P, Zhou LL, He ZY, Wu HM and Zhu JH: Reduced circulating levels of miR-433 and miR-133b are potential biomarkers for Parkinson's disease. Front Cell Neurosci. 11:1702017. View Article : Google Scholar : PubMed/NCBI
17	Tang XL, Lin L, Song LN and Tang XH: Hypoxia-inducible miR-152 suppresses the expression of WNT1 and ERBB3, and inhibits the proliferation of cervical cancer cells. Exp Biol Med (Maywood). 241:1429–1437. 2016. View Article : Google Scholar : PubMed/NCBI
18	Miao C, Zhang J, Zhao K, Liang C, Xu A, Zhu J, Wang Y, Hua Y, Tian Y, Liu S, et al: The significance of microRNA-148/152 family as a prognostic factor in multiple human malignancies: A meta-analysis. Oncotarget. 8:43344–43355. 2017. View Article : Google Scholar : PubMed/NCBI
19	Chen H, Liu H, Zou H, Chen R, Dou Y, Sheng S, Dai S, Ai J, Melson J, Kittles RA, et al: Evaluation of plasma miR-21 and miR-152 as diagnostic biomarkers for common types of human cancers. J Cancer. 7:490–499. 2016. View Article : Google Scholar : PubMed/NCBI
20	Dou H, Wang Y, Su G and Zhao S: Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer. Int J Clin Exp Med. 8:9291–9298. 2015.PubMed/NCBI
21	Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Wen YF, Cheng TT, Chen XL, Huang WJ, Peng HH, Zhou TC, Lin XD and Zeng LS: Elevated circulating tumor cells and squamous cell carcinoma antigen levels predict poor survival for patients with locally advanced cervical cancer treated with radiotherapy. PLoS One. 13:e02043342018. View Article : Google Scholar : PubMed/NCBI
24	Hung YC, Shiau YC, Chang WC, Kao CH and Lin CC: Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC). Neoplasma. 49:415–417. 2002.PubMed/NCBI
25	Nagamitsu Y, Nishi H, Sasaki T, Takaesu Y, Terauchi F and Isaka K: Profiling analysis of circulating microRNA expression in cervical cancer. Mol Clin Oncol. 5:189–194. 2016. View Article : Google Scholar : PubMed/NCBI
26	Granados-López AJ, Ruiz-Carrillo JL, Servín-González LS, Martínez-Rodríguez JL, Reyes-Estrada CA, Gutiérrez- Hernández R and López JA: Use of mature miRNA strand selection in miRNAs families in cervical cancer development. Int J Mol Sci. 18:E4072017. View Article : Google Scholar : PubMed/NCBI
27	Gao D, Zhang Y, Zhu M, Liu S and Wang X: miRNA expression profiles of HPV-infected patients with cervical cancer in the Uyghur population in China. PLoS One. 11:e01647012016. View Article : Google Scholar : PubMed/NCBI
28	Liu B, Ding JF, Luo J, Lu L, Yang F and Tan XD: Seven protective miRNA signatures for prognosis of cervical cancer. Oncotarget. 7:56690–56698. 2016.PubMed/NCBI
29	Zhao S, Yao D, Chen J and Ding N: Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer. Genet Test Mol Biomarkers. 17:631–636. 2013. View Article : Google Scholar : PubMed/NCBI
30	Zhao C, Lu F and Chen H, Zhao F, Zhu Z, Zhao X and Chen H: Clinical significance of circulating miRNA detection in lung cancer. Med Oncol. 33:412016. View Article : Google Scholar : PubMed/NCBI
31	Ponomaryova AA, Morozkin ES, Rykova EY, Zaporozhchenko IA, Skvortsova TE, Dobrodeev АY, Zavyalov AA, Tuzikov SA, Vlassov VV, Cherdyntseva NV, et al: Dynamic changes in circulating miRNA levels in response to antitumor therapy of lung cancer. Exp Lung Res. 42:95–102. 2016. View Article : Google Scholar : PubMed/NCBI
32	Qu K, Zhang X, Lin T, Liu T, Wang Z, Liu S, Zhou L, Wei J, Chang H, Li K, et al: Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: Evidence from comprehensive miRNA expression profiling analysis and clinical validation. Sci Rep. 7:16922017. View Article : Google Scholar : PubMed/NCBI
33	Sharova E, Grassi A, Marcer A, Ruggero K, Pinto F, Bassi P, Zanovello P, Zattoni F, D'Agostino DM, Iafrate M and Ciminale V: A circulating miRNA assay as a first-line test for prostate cancer screening. Br J Cancer. 114:1362–1366. 2016. View Article : Google Scholar : PubMed/NCBI
34	Yuwen DL, Sheng BB, Liu J, Wenyu W and Shu YQ: MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 21:2650–2658. 2017.PubMed/NCBI
35	Dasari S, Wudayagiri R and Valluru L: Cervical cancer: Biomarkers for diagnosis and treatment. Clin Chim Acta. 445:7–11. 2015. View Article : Google Scholar : PubMed/NCBI
36	Huang S, Li X and Zhu H: MicroRNA-152 targets phosphatase and tensin homolog to inhibit apoptosis and promote cell migration of nasopharyngeal carcinoma cells. Med Sci Monit. 22:4330–4337. 2016. View Article : Google Scholar : PubMed/NCBI